Want to see TSE:MSCL full AI Analyst Report?
Top Page
Satellos Bioscience
(TSX:MSCL)
Select Model
Select Model
Rating:49Neutral
Price Target:
C$12.00
▼(-8.26% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily held back by weak financial performance: no revenue, widening losses, and ongoing cash burn despite a debt-free balance sheet. Technicals are a relative positive with the price above key moving averages and neutral-to-positive momentum indicators. Valuation remains constrained by negative earnings and no indicated dividend support.
Positive Factors
Debt-Free Balance Sheet
The absence of debt lowers solvency and refinancing risk while preserving flexibility to fund clinical development. Meaningful equity provides a financial base, although continued losses could reduce this cushion over time.
Negative Factors
No Revenue
The absence of revenue means the company has not yet demonstrated commercial validation or internal funding capacity. Its outlook remains dependent on successful clinical progress, regulatory advancement and eventual product launch.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of debt lowers solvency and refinancing risk while preserving flexibility to fund clinical development. Meaningful equity provides a financial base, although continued losses could reduce this cushion over time.
Read all positive factors
Satellos Bioscience (MSCL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$256.93M
Dividend YieldN/A
Average Volume (3M)14.67K
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue GrowthN/A
EPS Growth-6.00%
CountryCA
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.12
Shares Outstanding21,216,438
10 Day Avg. Volume13,604
30 Day Avg. Volume14,674
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$35.82Price Target Upside173.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.23
Revenue Forecast (FY)N/A
Satellos Bioscience Business Overview & Revenue Model
Company Description
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, uti...
Satellos Bioscience Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.31M | -5.09K | -20.00K | -8.82M | -3.73M | -165.69K |
| EBITDA | -35.62M | -26.92M | -28.08M | -15.71M | -8.09M | -4.69M |
| Net Income | -34.26M | -25.31M | -28.10M | -15.89M | -11.32M | -15.51M |
Balance Sheet | ||||||
| Total Assets | 65.66M | 31.83M | 73.02M | 44.30M | 6.20M | 12.59M |
| Cash, Cash Equivalents and Short-Term Investments | 61.74M | 27.66M | 69.85M | 39.59M | 1.92M | 4.87M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.85M | 4.10M | 5.16M | 3.62M | 2.83M | 2.10M |
| Stockholders Equity | 59.81M | 27.73M | 67.86M | 40.67M | 3.37M | 10.48M |
Cash Flow | ||||||
| Free Cash Flow | -28.76M | -24.02M | -24.98M | -14.52M | -5.79M | -5.04M |
| Operating Cash Flow | -28.76M | -24.01M | -24.98M | -14.50M | -5.78M | -5.03M |
| Investing Cash Flow | -54.10M | -9.58M | 6.34M | -17.54M | -3.00K | 1.74M |
| Financing Cash Flow | 52.16M | 2.28M | 53.48M | 51.03M | 2.77M | 7.45M |
Satellos Bioscience Technical Analysis
Positive
13.08
Price Trends
12.45
Positive
11.04
Positive
11.14
Positive
Market Momentum
0.04
Positive
49.04
Neutral
14.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MSCL, the sentiment is Positive. The current price of 13.08 is below the 20-day moving average (MA) of 13.55, above the 50-day MA of 12.45, and above the 200-day MA of 11.14, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 49.04 is Neutral, neither overbought nor oversold. The STOCH value of 14.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MSCL.
Satellos Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$145.12M | -43.86 | -21.54% | ― | ― | 77.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$256.93M | -4.79 | -71.28% | ― | ― | -6.00% | |
48 Neutral | C$74.05M | -26.28 | 70.15% | ― | ― | 16.99% | |
46 Neutral | C$36.87M | -2.13 | -360.29% | ― | ― | -33.27% |
* Healthcare Sector Average
TSE:MSCL
Satellos Bioscience
12.85
5.41
72.72%
TSE:ARCH
Arch Biopartners
1.01
-0.68
-40.24%
TSE:MDNA
Medicenna Therapeutics Corp
0.47
-0.59
-55.66%
TSE:HBP
Helix BioPharma
1.79
0.45
33.58%
TSE:METX
ME Therapeutics Holdings, Inc.
2.50
-1.50
-37.50%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.